Measurement Error and Equating Error in Power Analysis

Power analysis is a fundamental prerequisite for conducting scientific research. Without power analysis the researcher has no way of knowing whether the sample size is large enough to detect the effect he or she is looking for. This paper demonstrates how psychometric factors such as measurement error and equating error affect the power of statistical tests. The overall finding is that measurement error and equating error reduce power and inflate sample size requirements. It is recommended that researchers, where appropriate, incorporate these sources of error in conducting power analysis. If either of these two sources of error are present in the data but not accounted for in the power analysis, then power will be underestimated and sample size requirements will be underestimated. Accessed 3,877 times on https://pareonline.net from August 08, 2016 to December 31, 2019. For downloads from January 1, 2020 forward, please click on the PlumX Metrics link to the right

Making Sense of Your World: A Biblical Worldview

Making Sense of Your World offers a basic, accessible introduction to biblical worldview that covers all aspects of world-view thinking. Part One compares the basic worldviews, Part Two contrasts (and seeks to defend) the biblical worldview with the others, and Part Three constructs a biblical worldview in four key areas. This book is an overview; the Christian thinker is invited to continue his or her study through the recommended readings at the end of each chapter an ongoing task Paul labels the renewing of our minds (Romans 12:2).https://digitalcommons.cedarville.edu/faculty_books/1005/thumbnail.jp

Hypoxia as a target for drug combination therapy of liver cancer

Hepatocellular carcinoma (HCC) is the third most frequentcause of cancer deaths worldwide. The standard of care for intermediate HCC is transarterial chemoembolization, which combines tumour embolization with locoregional delivery of the chemotherapeutic doxorubicin. Embolization therapies induce hypoxia, leading to the escape and proliferation of hypoxia-adapted cancer cells. The transcription factor that orchestrates responses to hypoxia is hypoxia-inducible factor 1 (HIF-1). The aim of this work is to show that targeting HIF-1 with combined drug therapy presents an opportunity for improving outcomes for HCC treatment. HepG2 cells were cultured under normoxic and hypoxic conditions exposed to doxorubicin, rapamycin and combinations thereof, and analyzed for viability and the expression of hypoxia-induced HIF-1α in response to these treatments. A pilot study was carried out to evaluate the antitumour effects of these drug combinations delivered from drug-eluting beads in vivo using an ectopic xenograft murine model of HCC. A therapeutic doxorubicin concentration that inhibits the viability of normoxic and hypoxic HepG2 cells and above which hypoxic cells are chemoresistant was identified, together with the lowest effective dose of rapamycin against normoxic and hypoxicHepG2 cells. It was shown that combinations of rapamycinand doxorubicin are more effective than doxorubicin alone. Western Blotting indicated that both doxorubicin and rapamycin inhibit hypoxia-induced accumulation of HIF-1α. Combination treatments were more effective in vivo than either treatment alone. mTOR inhibition can improve outcomes of doxorubicin treatment in HCC Anti-Cancer

Electron and proton heating by solar wind turbulence

Previous formulations of heating and transport associated with strong magnetohydrodynamic (MHD) turbulence are generalized to incorporate separate internal energy equations for electrons and protons. Electron heat conduction is included. Energy is supplied by turbulent heating that affects both electrons and protons, and is exchanged between them via collisions. Comparison to available Ulysses data shows that a reasonable accounting for the data is provided when (i) the energy exchange timescale is very long and (ii) the deposition of heat due to turbulence is divided, with 60% going to proton heating and 40% into electron heating. Heat conduction, determined here by an empirical fit, plays a major role in describing the electron data

1977: Abilene Christian College Bible Lectures - Full Text

Seeking The Lost Being the Abilene Christian University Annual Bible Lectures 1977 Published by ABILENE CHRISTIAN UNIVERSITY Book Store ACU Station Abilene, Texas 7960

Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer

DC Bead is a drug delivery embolisation system that can be loaded with doxorubicin or irinotecan for the treatment of a variety of liver cancers. In this study we demonstrate that the topoisomerase I inhibitor topotecan hydrochloride can be successfully loaded into the DC Bead sulfonate-modified polyvinyl alcohol hydrogel matrix, resulting in a sustained-release drug eluting bead (DEBTOP) useful for therapeutic purposes. The in vitro drug loading capacity, elution characteristics and the effects on mechanical properties of the beads are described with reference to our previous work with irinotecan hydrochloride (DEBIRI). Results showed that drug loading was faster when the solution was agitated compared to static loading and a maximum loading of ca. 40–45 mg topotecan in 1 ml hydrated beads was achievable. Loading the drug into the beads altered the size, compressibility moduli and colour of the bead. Elution was shown to be reliant on the presence of ions to perform the necessary exchange with the electrostatically bound topotecan molecules. Topotecan was shown by MTS assay to have an IC50 for human pancreatic adenocarcinoma cells (PSN-1) of 0.22 and 0.27 lM compared to 28.1 and 19.2 lM for irinotecan at 48 and 72 h, respectively. The cytotoxic efficacy of DEBTOP on PSN-1 was compared to DEBIRI. DEPTOP loaded at 6 & 30 mg ml-1, like its free drug form, was shown to be more potent than DEBIRI of comparable doses at 24, 48 & 72 h using a slightly modified MTS assay. Using a PSN-1 mouse xenograft model, DEBIRI doses of 3.3–6.6 mg were shown to be well tolerated (even with repeat administration) and effective in reducing the tumour size. DEBTOP however, was lethal after 6 days at doses of 0.83–1.2 mg but demonstrated reasonable efficacy and tolerability (again with repeat injection possible) at 0.2–0.4 mg doses. Care must therefore be taken when selecting the dose of topotecan to be loaded into DC Bead given its greater potency and potential toxicity